Ketamine Therapy for Suicidal Thoughts & Ideation
Rapid Relief for Suicidal Ideation, Beyond Antidepressants
Understanding Suicidal Ideation
Among the most clinically urgent areas of psychiatric need, suicidal ideation now has a targeted, FDA-approved treatment option — and a rapidly growing body of research supporting ketamine’s unique anti-suicidal effects, independent of its antidepressant action.
Suicidal ideation exists on a spectrum — from passive thoughts that life isn’t worth living, to active plans with intent and means. Both passive and active ideation are clinically serious, both deserve treatment, and both have been studied in ketamine research. Having these thoughts does not make someone “dangerous” or beyond help. It signals that a person is in significant psychological pain and needs immediate, effective care.
One of the most painful gaps in psychiatric treatment has historically been timing: conventional antidepressants take four to six weeks to produce meaningful effects — but a person in acute suicidal crisis cannot safely wait that long. It is precisely this gap that has driven intense scientific interest in ketamine’s remarkably rapid anti-suicidal properties.
“Ketamine is highly effective in decreasing suicidal ideation and suicide risk, and the acute reductions in suicidality are maintained with ongoing treatment.”
— Dr. Brandon Hamm, Northwestern University Feinberg School of Medicine, Psychiatry Advisor, 2025
Research has also established something important and counterintuitive: ketamine’s anti-suicidal effects appear to be at least partially independent of its antidepressant effects. This suggests ketamine may target neurobiological pathways specific to suicidal cognition — not merely reducing suicidal thoughts as a downstream result of lifting mood.
FDA Approval: Spravato® for MDD with Acute Suicidal Ideation
In 2020, the FDA granted a second approval to esketamine nasal spray (Spravato®) — specifically for the treatment of depressive symptoms in adults with major depressive disorder (MDD) experiencing acute suicidal ideation or behavior. This makes Spravato® the first and only FDA-approved medication for this indication, and the only ketamine-derived treatment with regulatory backing for suicidal ideation.
The FDA-approved protocol for this indication is 84 mg administered twice per week for four weeks, in conjunction with an oral antidepressant, in a certified healthcare setting with mandatory two-hour post-dose monitoring. BHWWC is a certified Spravato® provider operating under the required REMS program.
2020
FDA approval of Spravato® (esketamine) specifically for MDD with acute suicidal ideation or behavior
<24 hrs
Timeframe in which ketamine reduced suicidal ideation severity in more than half of patients across 10 controlled trials
37%
Lower risk of suicidal ideation vs. other antidepressants at 1–7 days in 514,988-patient national cohort study
The Spravato® approval was supported by two identically designed Phase 3 trials examining its effect in patients with active suicidal ideation. In clinical comparison data, the suicidal ideation treatment response rate was 46.2% for IV ketamine and 58.8% for Spravato® — with both treatments showing meaningful anti-suicidal benefit.
What the Research Shows: IV Ketamine
The evidence base for IV ketamine’s anti-suicidal effects is substantial. A pivotal 2018 meta-analysis in the American Journal of Psychiatry (Wilkinson et al.) pooled individual participant data from 10 controlled trials and found that a single IV ketamine infusion rapidly reduced the severity of suicidal thinking within 24 hours in more than half of patients — with benefits observed for up to one week. Effect sizes were moderate to large (Cohen’s d = 0.48–0.85).
A 2024 large-scale real-world study using the TriNetX US Collaborative Network — drawing on electronic health records from more than 514,000 patients with recurrent major depression — found that ketamine prescription was associated with a significantly and durably lower risk of suicidal ideation compared to other antidepressants: 37% lower risk at one to seven days, 31% lower at one to ninety days, and 22% lower at up to 270 days.
A 2024 meta-analysis of 49 independent clinical trials involving nearly 4,000 participants (published in the Journal of Psychiatric Research) found that after a single ketamine administration, suicidal ideation significantly decreased as early as 4 hours, with peak effects at 24 hours — and effects persisting in studies followed for up to one month.
An effect beyond antidepressant action
A randomized controlled trial by Price et al. (2014) found that 53% of ketamine-treated patients scored zero on all three explicit suicide measures at 24 hours — compared to 24% in the active placebo (midazolam) group. Crucially, the anti-suicidal effect was also observed on an implicit measure of suicidal cognition (Implicit Association Test), and the effect was largest in patients with the highest baseline suicidal cognition — suggesting a specific mechanism beyond general mood elevation.
Our Approach to Suicidal Ideation
We treat patients experiencing suicidal ideation with the utmost clinical seriousness and compassion. Our approach is grounded in the understanding that suicidal thoughts are a symptom of treatable illness — not a character failing, and not a reason to be turned away from care.
Before initiating any treatment, we conduct a thorough clinical evaluation that includes assessment of current ideation, plan, and intent; history of prior attempts; current psychiatric diagnosis and treatment; support systems; and safety planning. We coordinate closely with your treating psychiatrist and, where appropriate, with crisis services.
Who we may be able to help
• Adults with MDD and active suicidal ideation who meet criteria for Spravato® treatment — the FDA-approved option for this specific population
• Patients with passive suicidal ideation in the context of treatment-resistant depression
• Individuals whose psychiatric team supports ketamine evaluation as part of a broader safety and treatment plan
• APatients transitioning from higher levels of care (inpatient or partial hospitalization) who need rapid stabilization
What we are not
BHWWC is an outpatient clinic. We are not equipped to manage psychiatric emergencies, active suicidal crises requiring hospitalization, or situations where a patient cannot safely wait for a scheduled appointment. If you are in crisis, please call or text 988, call 911, or go to your nearest emergency room.